Video

Dr. Agarwal on the Progression of the COSMIC-021 Trial in mCRPC

Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program, Huntsman Cancer Institute, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer (mCRPC).

The multicenter, open-label, phase 1b trial tested the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in a wide variety of patient populations, says Agarwal. Based on encouraging efficacy and safety data, cohort 6, which consisted of patients with mCRPC, was expanded to a total of 130 patients. At this point, a large phase 3 trial had been planned.

The phase 3 trial will accrue patients all over the globe, including the United States. This study will further evaluate the combination of cabozantinib and atezolizumab in patients mCRPC, Agarwal concludes.

Related Videos
Dasom (Caroline) Lee, MD
William K. Oh, MD
Olalekan O. Oluwole, MD
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Axel Merseburger, MD, PhD
Shilpa Gupta, MD
Drs Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD